BRIEF-Nektar Therapeutics and Daiichi Sankyo Europe sign European licensing agreement for onzeald experimental treatment for breast cancer and brain metastases

June 1 (Reuters) - Nektar Therapeutics Says Also Entitled To Significant Double
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.